Evidence map›Paper›PMID 16297160›Full record

ArticleClinical and experimental immunology2005

Macrophage activation switching: an asset for the resolution of inflammation.

F Porcheray, S Viaud, A-C Rimaniol, C Léone, B Samah, N Dereuddre-Bosquet, D Dormont, G Gras

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04663126 (Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma), which is not on this map. Cited by 407 papers.

0numbers the graph read from it
0cells of the map it votes in
407citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04663126 early_phase1terminatednot on this mapstarted 2021, after this paper: background citation

Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma

TypeinterventionalSponsorJohn O. PriorRan2021 to 2023Enrolled5ConditionsMelanomaArmsTc-99m tilmanocept
3 · Its place in the literature

Who cites it

407 citing papers in PubMed, 827 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Rodent monocyte-derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians.Developmental dynamics : an official publication of the American Association of Anatomists · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

347 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

F PorcherayLaboratoire de Neuro-Immuno-Virologie, Service de Neurovirologie UMR-E1, Université Paris-Sud, Centre de Recherches du Service de Santé des Armées, IPSC, Fontenay aux Roses, France.
S Viaud
A-C Rimaniol
C Léone
B Samah
N Dereuddre-Bosquet
D Dormont
G Gras
Service de Santé des Armées · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversité Paris-Sud · FRCEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages play a central role in inflammation and host defence against microorganisms, but they also participate actively in the resolution of inflammation after alternative activation. However, it is not known whether the resolution of inflammation requires alternative activation of new resting monocytes/macrophages or if proinflammatory activated macrophages have the capacity to switch their activation towards anti-inflammation. In order to answer this question, we first characterized differential human macrophage activation phenotypes. We found that CD163 and CD206 exhibited mutually exclusive induction patterns after stimulation by a panel of anti-inflammatory molecules, whereas CCL18 showed a third, overlapping, pattern. Hence, alternative activation is not a single process, but provides a variety of different cell populations. The capacity of macrophages to switch from one activation state to another was then assessed by determining the reversibility of CD163 and CD206 expression and of CCL18 and CCL3 production. We found that every activation state was rapidly and fully reversible, suggesting that a given cell may participate sequentially in both the induction and the resolution of inflammation. These findings may provide new insight into the inflammatory process as well as new fields of investigation for immunotherapy in the fields of chronic inflammatory diseases and cancer.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticAnti-Inflammatory AgentsCD163 AntigenCells, CulturedCell SurvivalChemokine CCL3Chemokine CCL4Chemokines, CCCytokinesFlow CytometryHLA-DR AntigensHumansInflammationLectins, C-TypeMacrophage ActivationAntigens, CDAntigens, Differentiation, MyelomonocyticAnti-Inflammatory AgentsCCL18 protein, humanCcl3 protein, mouseCD163 AntigenChemokine CCL3Chemokine CCL4Chemokines, CCCytokinesHLA-DR AntigensLectins, C-TypeMacrophage Inflammatory ProteinsMannose-Binding LectinsMannose ReceptorReceptors, Cell Surface

Identifiers

PMID16297160
PMCPMC1809537
OpenAlexW1983220630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.